Thus, ALS mice injected with the Ad-VEGF+Ad-ANG combination showed a 2–3 week delay in manifestation of the disease, higher motor activity at the advanced stages of the disease, and increase in the lifespan (Ismailov et al., 2014). The gene discussed is VEGFA; the disease is amyotrophic lateral sclerosis.